Caristo Diagnostics

Life Sciences  •  South East  •  Early Stage

Caristo’s technology aims to revolutionise diagnosis and treatment, enabling physicians to identify patients with the highest heart attack risk and prescribe effective, personalised treatments that can prevent a fatal heart attack.


Investment date

March 2021

Head office


Caristo was founded in 2018 by cardiologists at the University of Oxford, following a decade of scientific research and technical development, and is now a leader in supporting the transformation of healthcare from treatment-based medicine to prevention.

To date, the company has raised a total of £10.2 million. It recently closed a successful investment round led by BGF and existing investors, including Oxford Sciences Innovation (OSI), Longwall Ventures and the Oxford Technology & Innovation Fund (OTIF).